CClinicalTrials.gg
CompletedNCT06803810P2PUpdated Feb 6, 2026

Peer to Peer (P2P): Mental Health Interventions With Persons With Substance Use Disorders

An interventional study of P2P Intervention in Standard of Care and P2P Intervention, sponsored by Prisma Health-Upstate. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Prisma Health-Upstate · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study provides substance use and mental health peer support services to address behavioral health disparities in rural areas. Specifically, the project aims to address persistent mental health symptoms, such as anxiety and depression, that become barriers to care for patients working towards long-term recovery from co-occurring mental health and substance use disorders. Participants will be assessed and evaluated for opioid use disorder (OUD), social determinants of health (SDoH), and infectious diseases by a nurse practitioner and a social worker. A certified peer support specialist (CPSS) will provide additional support, connecting patients to sustainable mental health resources and implementing a modified version of the Friendship Bench intervention, which involves six weekly 45-minute problem-solving therapy sessions with the option to participate in six or more peer support sessions. The CPSS will follow the patient for up to 12 weeks.

02

Conditions studied

  • Standard of Care
  • P2P Intervention
03

In context

Lead sponsor

Prisma Health-Upstate is the lead sponsor of 74 studies on the registry; 7 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 10 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of OUD via Diagnostic Statistical Manual (DSM)-V Text Revision (TR)
  • Receiving MOUD through the Mobile Recovery Program for at least 3 months
  • Age 18 or older
  • Moderate to Severe Depression with or without co-occurring anxiety as determined by PHQ-9 conducted during the most recent MRP clinical visit

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive, medical, or psychiatric disability that could impair ability to perform study-related activities as determined by the MRP clinician or principal investigator.
  • Unable to read/speak English
  • Unable to read and comprehend the consent materials and other study materials
  • Current suicidal ideation based on the Patient Health Questionnaire-9
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • No intervention
    Standard of Care

    This group will complete a baseline, week 6, and week 12 study visit. Participants will complete research visits (in-person or virtually) at which time they will complete a series of questionnaires.

  • Experimental
    P2P Intervention

    This group will complete the same study visits as the standard care group with an additional week 3 visit and 6 CPSS-led therapy intervention sessions. These CPSS led sessions will be completed by the end of the 12week study period. At each study visit you will complete questionnaires.

    Behavioral: P2P Intervention

Interventions

  • BehavioralP2P Intervention

    This group will complete the same study visits as the standard care group with an additional week 3 visit and 6 CPSS-led therapy intervention sessions. These CPSS led sessions will be completed by the end of the 12week study period. At each study visit you will complete questionnaires.

06

What researchers measure

Primary outcomes

  1. Reduction in depressive symptoms

    Reduce depression symptoms as measured by the PHQ-9

    Time frame: 12 weeks

07

Study locations

1 site
  • Prisma Health
    Greenville, South Carolina 29605, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06803810
Lead sponsor
Prisma Health-Upstate
Collaborators
South Carolina Center for Rural and Primary Healthcare
Responsible party
Sponsor
First posted
Jan 31, 2025
Start date
Nov 11, 2024
Primary completion
Dec 29, 2025
Completion
Dec 29, 2025
Last update
Feb 6, 2026

Study contacts

Alain Litwin
principal investigator · Prisma Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion